News Lundbeck brings third Parkinson's drug into clinic Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.
News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Lundbeck trial investigates genetic causes of depression New study with 23andMe and Milken Institute looks to determine causes of depression.
News Lundbeck enlists IBM Watson to aid psychiatric drug research Collaboration will initially focus on Parkinson's disease and schizophrenia.
News Lundbeck epilepsy injection approved in US New carbamazepine formulation when oral dosing not feasible.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.